Newmanbrain

Newmanbrain is pioneering the future of brain health with THEIA®, the world's first non-invasive, objective, and highly accurate system for assessing mild cognitive impairment (MCI). By combining a cloud-based software platform with a lightweight headset, THEIA® leverages fNIRS (functional near-infrared spectroscopy) to assess hemodynamics in the prefrontal cortex while the patient performs arithmetic tasks. Using advanced machine learning algorithms, THEIA® accurately analyzes this data to determine the likelihood of a patient suffering from MCI. Newmabrain's mission is to accelerate the development of brain treatments while simultaneously reducing the costs and wait times traditionally associated with diagnosing and monitoring neurological conditions. *Theia is pending CE marking. DISCLAIMER The information shared on this page is for informational purposes only and should not be construed as medical advice or guidance. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment options. Reliance on any information provided on this page is at your own risk. The company is not responsible for the accuracy, content, or reliability of any third-party materials, links, or comments that may appear on this page. We do not endorse or verify the information provided by others. We reserve the right to remove any posts, comments, or content that we deem inappropriate, including but not limited to discriminatory, offensive, promotional, confidential, sensitive, false, misleading, or plagiarized information. This page is intended to foster a professional and respectful environment. This page is not intended to replace professional medical advice, diagnosis, or treatment. If you are experiencing a medical emergency, please contact a healthcare professional immediately. Theia is pending CE marking.